Skip to content

BBNX BBNX Operating margin

Operating margin at other companies

Insulet logo
InsuletPODD
17.5%+2.0pp
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-8.2%-2.9pp
Medtronic logo
MedtronicMDT
17.8%0.0pp
AdaptHealth logo
AdaptHealthAHCO
8%+6.9pp
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
59.3%+9.0pp

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Calculated from BBNX’s reported figures.

Based on trailing twelve months.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's operating margin?
BBNX (BBNX) reported operating margin of -70.1% in Q1 2026.
How has BBNX's operating margin changed year-over-year?
BBNX's operating margin increased by 10.0% year-over-year, from -78% to -70.1%.
What is the long-term trend for BBNX's operating margin?
Over 2 years (2023 to 2025), BBNX's operating margin has grown at a -51.1% compound annual growth rate (CAGR), from -298.9% to -71.5%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.